Skip to content
Biosion
  • About
    • Executive Team
    • Development Team
    • Advisory Board
    • Careers
  • Platform
    • H3 Antibody Technology
    • SynTracer™ Internalization Platform
    • FlexibodyTM Bispecific Platform
  • Pipeline
  • Partners
  • News
  • Contact
  • English
  • 中文
  • About
    • Executive Team
    • Development Team
    • Advisory Board
    • Careers
  • Platform
    • H3 Antibody Technology
    • SynTracer™ Internalization Platform
    • FlexibodyTM Bispecific Platform
  • Pipeline
  • Partners
  • News
  • Contact
  • English
  • 中文

Careers

Join Our Team and Grow With Us

At Biosion, we are innovators, leaders, and collaborators. We love what we do and who we work with. And at the heart of everything we do is an intense desire to innovate for cures and to improve quality of life.

Job opportunities

H3 Antibody Technology

Biosion has developed a proprietary, state-of-the-art platform called H3 Antibody Technology that enables discovery of multiple therapeutic candidates with superior properties.

The H3 platform allows for:

  • High-throughput screening and ranking of thousands of target binders
  • High-content screening to facilitate identification of superior lead candidates
  • High-efficiency that guarantees greater productivity and success

The combination of our proprietary immunization strategies and robust screening processes allow for the identification of a large number of clones with superior properties 

The robustness of Biosion’s high-throughput high-content screening process combined with the availability of their extensive hybridoma-derived antibody collections significantly reduces the cost associated with the daunting task of antibody drug discovery.

With the application of H³ antibody technology, Biosion core team member has successfully accomplished over 100 antibody development projects for international diagnostic product companies, biopharmaceutical corporations, major universities, and medical schools.

 

High-Throughput

 

 

  • Generating a large hybridoma pool for superior leads identification
  • 15-25x higher than industry average (1000~5000 antigen-positive hybridomas per project)

High-Content

 

 

  • Identifying leads with the desired properties in the early stage
  • Multiple parameter screening simultaneously

High-Efficiency

 

 

  • Identifying lead candidates with the maximized ROI
  • 2-10x higher than industry average

Technical & market validation: Abbvie, SDIX, ImmunoVir, Hengrui, CTTQ, Salubris, etc
Deliverables: MVR-T3011 (FIC, Ph-I/IIa), SHR-1806(BIC, Ph-I), TQC2731 (BIC, Ph-I)

Committed to bring next generation innovative therapeutics to treat immune and oncologic diseases.

LinkedIn

CHINA

BIOSION, INC.

5th Floor, Building D
3-1 Zhongdan Unit
South Longshan Rd
Jiangbei New District
Nanjing, Jiangsu, China 210061
Tel: (86) 025-5829-1977

USA

BIOSION USA, INC.

1 Innovation Way, Suite 300
Newark, DE 19711
Tel: 1-302-998-5126

Australia

BIOSION AUSTRALIA PTY LTD.

58 Gipps Street
Collingwood, Victoria 3066
Tel: 1-302-998-5126

Website by Bartlett Interactive
Terms Privacy
© 2022. Biosion All Rights Reserved.
Close Bitnami banner
Bitnami